Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation

BMC Health Services Research

Volumn 6, Issue , 2006, Pages

  Fenwick, Elisabeth ^a   Marshall, Deborah A ^b   Levy, Adrian R ^c   Nichol, Graham ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ST JOSEPH S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; CARDIOVASCULAR AGENT;

COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; INTERVENTION STUDY; MANAGEMENT STYLE; MORTALITY; REVIEW; RISK FACTOR; STROKE PATIENT; SURVIVAL RATE; AGED; ATRIAL FIBRILLATION; BAYES THEOREM; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLASSIFICATION; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; SURVIVAL; TREATMENT OUTCOME; UNCERTAINTY;

AGED; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BAYES THEOREM; CARDIOVASCULAR AGENTS; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; HEART RATE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME; UNCERTAINTY;

EID: 33747115307     PISSN: 14726963     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-6-52     Document Type: Review

References (27)

1. Bower P, Byford S, Barber J, Beecham J, Simpson S, Friedli K, Corney R, King M, Harvey I: Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses. BMJ 2003, 326:1247-1250.
2. Byford S, Knapp M, Greenshields J, Ukoumunne O, Jones V, Thompson S, Tyrer P, Schmidt U, Davidson K, Group P: Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychol Med 2003, 33(6):977-986.
3. Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper N, Abrams K, Claxton K, Miller D, Group CEoMSTS: Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in mulitple sclerosis. BMJ 2003, 326:522-524.
4. Delaney B, Wilson S, Roalfe A, Roberts L, Redman V, Wearn A, Briggs A, Hobbs F: Cost effectiveness of initial endoscopy for dypepsia in patients over age 50 years: a randomised controlled trial in primary care. Lancet 2000, 356:1965-1969.
5. Drummond M, Becker D, Hux M, Chancellor J, Duprat-Lomon I, Kubin R, Sagnier P: An economic evaluation of sequential i.v./ po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003, 124(2):526-535.
6. Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 2000, 320(7246):1373-1378.
7. Manns B, Lee H, Doig C, Johnson D, Donaldson C: An economic evaluation of activated protein C treatment for severe sepsis. New England Journal of Medicine 2002, 347(13):993-1000.
8. Multicentre Aneurysm Screening Group: Multicentre aneurysm screening study (MASS):cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from a randomised controlled trial. BMJ 2002, 325:1135-1138.
9. Ramsey S, Berry K, Etzioni R, Kaplan R, Sullivan S, Wood D, Group NETTR: Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. New England Journal of Medicine 2003, 348(21):2092-2102.
10. Sheldon R, O'Brien B, Blackhouse G, Goeree R, Mitchell B, Klein G, Roberts R, Gent M, Connolly S: Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation 2001, 104(14):1622-1626.
11. UK Prospective Diabetes Study Group: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998, 317:720-726.
12. Marshall D, Levy A, Vidaillet H, Fenwick E, Slee A, Blackhouse G, Greene H, Wyse G, Nichol G, O'Brien B, et al.: Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Annals of Internal Medicine 2004, 141(9):653-661.
13. Fenwick E, Claxton K, Sculpher M: Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ 2001, 10:779-787.
14. Wyse G, Waldo A, DiMarco J, Domanski M, Rosenberg Y, Schron E: A comparison of rate control and rhythm control in patients with atrial fibrillation. New England Journal of Medicine 2002, 347:1825-1833.
15. Black W: The CE plane: A graphic representation of costeffectiveness. Medical Decision Making 1990, 10:212-214.
16. Stinnett AA, Mullahy J: Net Health Benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998, 18(2 Suppl):S68-80.
17. Briggs AH, Gray A: Handling uncertainty when performing economic evaluation of healthcare interventions. Health Tech Assess 1999, 3:.
18. Briggs AH, Wonderling DE, Mooney CZ: Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Economics 1997, 6:327-340.
19. Lothgren M, Zethraeus N: Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics 2000, 9:623-630.
20. Willan A, O'Brien B: Confidence intervals for cost-effectiveness analysis ratios: an application of Fieller's theorem. Health Economics 1996, 5(4):297-305.
21. Heitjan DF, Moskowitz AJ, Whang W: Problems with interval estimates of the incremental cost-effectiveness ratio. Medical Decision Making 1999, 19(1):9-15.
22. O'Hagan A, Stevens JW, Montmartin J: Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 2000, 17:339-349.
23. Briggs A, Fenn P: Confidence intervals or surfaces ? Uncertainty on the cost-effectiveness plane. Health Economics 1998, 7:723-740.
24. Van Hout B, Al M, Gordon G, Rutten F: Costs, effects and c/eratios alongside a clinical trial. Health Economics 1994, 3:309-319.
25. O'Brien B, Briggs A: Analysis of uncertainty in health care costeffectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research 2002, 11:455-468.
26. Fenwick E, O'Brien B, Briggs A: Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Economics 2004, 13:405-415.
27. Bahnson TD, Grant AO: To be or not to be in normal sinus rhythm: What do we really know? Annals of Internal Medicine 2004, 141(9):727-729.